ATE523507T1 - Piperidin-gpcr-agonisten - Google Patents

Piperidin-gpcr-agonisten

Info

Publication number
ATE523507T1
ATE523507T1 AT08702095T AT08702095T ATE523507T1 AT E523507 T1 ATE523507 T1 AT E523507T1 AT 08702095 T AT08702095 T AT 08702095T AT 08702095 T AT08702095 T AT 08702095T AT E523507 T1 ATE523507 T1 AT E523507T1
Authority
AT
Austria
Prior art keywords
gpcr agonists
piperidine
piperidine gpcr
agonists
obesity
Prior art date
Application number
AT08702095T
Other languages
German (de)
English (en)
Inventor
Matthew Fyfe
John Keily
Simon Swain
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0700123A external-priority patent/GB0700123D0/en
Priority claimed from GB0719760A external-priority patent/GB0719760D0/en
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Application granted granted Critical
Publication of ATE523507T1 publication Critical patent/ATE523507T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT08702095T 2007-01-04 2008-01-04 Piperidin-gpcr-agonisten ATE523507T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0700123A GB0700123D0 (en) 2007-01-04 2007-01-04 GPCR agonists
GB0719760A GB0719760D0 (en) 2007-10-10 2007-10-10 GPCR agonists
PCT/GB2008/050010 WO2008081204A1 (en) 2007-01-04 2008-01-04 Piperidine gpcr agonists

Publications (1)

Publication Number Publication Date
ATE523507T1 true ATE523507T1 (de) 2011-09-15

Family

ID=39203133

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08702095T ATE523507T1 (de) 2007-01-04 2008-01-04 Piperidin-gpcr-agonisten

Country Status (16)

Country Link
US (1) US20100048632A1 (enExample)
EP (2) EP2114933B1 (enExample)
JP (1) JP2010514828A (enExample)
AT (1) ATE523507T1 (enExample)
BR (1) BRPI0806498A2 (enExample)
CA (1) CA2674348A1 (enExample)
CY (1) CY1112483T1 (enExample)
DK (1) DK2114933T3 (enExample)
EA (1) EA015129B1 (enExample)
ES (1) ES2373181T3 (enExample)
HR (1) HRP20110852T1 (enExample)
PL (1) PL2114933T3 (enExample)
PT (1) PT2114933E (enExample)
RS (1) RS52065B (enExample)
SI (1) SI2114933T1 (enExample)
WO (1) WO2008081204A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20081849A1 (es) * 2007-01-04 2009-01-26 Prosidion Ltd Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
JP2010539152A (ja) 2007-09-10 2010-12-16 プロシディオン・リミテッド 代謝障害の治療のための化合物
GB0812648D0 (en) * 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812649D0 (en) * 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
US8481731B2 (en) 2009-06-24 2013-07-09 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
US8293729B2 (en) 2009-06-24 2012-10-23 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
JP2013522279A (ja) 2010-03-18 2013-06-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ
GB201006167D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201006166D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
ITMI20100770A1 (it) 2010-05-03 2011-11-04 Dipharma Francis Srl Procedimento per la preparazione di 3-(4-piridinil)-propanolo e suoi intermedi
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
ITMI20100984A1 (it) 2010-05-31 2011-12-01 Dipharma Francis Srl Procedimento per la preparazione di ossadiazoli
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
KR20130138768A (ko) 2010-09-01 2013-12-19 아레나 파마슈티칼스, 인크. 5-ｈｔ2ｃ 아고니스트의 신속-용해성 투여 형태
KR20180118801A (ko) 2010-09-01 2018-10-31 에자이 알앤드디 매니지먼트 가부시키가이샤 체중 관리에 유용한 5-ｈｔ2ｃ 작동제의 변형-방출 투여 형태
JP2013539470A (ja) 2010-09-01 2013-10-24 アリーナ ファーマシューティカルズ， インコーポレイテッド ロルカセリンと光学活性な酸との塩
KR20130101524A (ko) 2010-09-01 2013-09-13 아레나 파마슈티칼스, 인크. 5-ｈｔ2ｃ 아고니스트의 비-흡습성 염
GB201114389D0 (en) 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
AR083904A1 (es) 2010-11-18 2013-04-10 Prosidion Ltd Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos
KR101913619B1 (ko) 2011-06-09 2018-12-28 리젠 파마슈티컬스 소시에떼 아노님 Gpr-119의 조절제로서의 신규한 화합물
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013187646A1 (en) 2012-06-12 2013-12-19 Chong Kun Dang Pharmaceutical Corp. Piperidine derivatives for gpr119 agonist
HUE045926T2 (hu) 2013-11-26 2020-01-28 Chong Kun Dang Pharmaceutical Corp Amid-származékok GPR119 agonistákhoz
KR101726819B1 (ko) * 2014-10-27 2017-04-13 동아에스티 주식회사 Gpr119 작용 활성을 갖는 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3576810A (en) * 1968-06-20 1971-04-27 Robins Co Inc A H 1-substituted-3-(-4)-aroylpiperidines
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
DE4222565A1 (de) * 1992-07-09 1994-01-13 Hoechst Ag Meta-substituierte Sechsringaromaten zur Verwendung in Flüssigkristallmischungen
US6100042A (en) 1993-03-31 2000-08-08 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
DE4311968A1 (de) * 1993-04-10 1994-10-20 Hoechst Ag Smektische Flüssigkristallmischung
DE4311967A1 (de) * 1993-04-10 1994-10-13 Hoechst Ag Smektische Flüssigkristallmischung
AU7193394A (en) 1993-08-13 1995-03-14 Zeneca Limited Thia- and oxadiazole derivatives and their use as fungicides or insecticides
JPH11513382A (ja) * 1995-10-20 1999-11-16 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング ５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法
CA2262569A1 (en) 1996-08-09 1998-02-19 Norihito Ohi Benzopiperidine derivatives
GB9719496D0 (en) 1997-09-13 1997-11-19 Glaxo Group Ltd G protien chimeras
CA2344591A1 (en) 1998-09-01 2000-03-09 Basf Aktiengesellschaft Methods for improving the function of heterologous g protein-coupled receptors
US6221660B1 (en) 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
GB0109103D0 (en) 2001-04-11 2001-05-30 Pfizer Ltd Novel compounds
FR2829027A1 (fr) 2001-08-29 2003-03-07 Aventis Pharma Sa Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson
FR2829028B1 (fr) 2001-08-29 2004-12-17 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
JP2005507875A (ja) 2001-08-31 2005-03-24 ユニバーシティ オブ コネチカット カンナビノイド受容体に作用する新規なピラゾール類似体
CN101659639A (zh) 2001-09-21 2010-03-03 索尔瓦药物有限公司 具有cb1-拮抗活性的新的4,5-二氢-1h-吡唑衍生物
KR100950430B1 (ko) 2001-09-21 2010-04-02 솔베이 파마슈티칼스 비. 브이 효력있는 ｃｂ1-길항 작용을 가지는4,5-디하이드로-1ｈ-피라졸 유도체
TWI231757B (en) 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
FR2831883B1 (fr) 2001-11-08 2004-07-23 Sanofi Synthelabo Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
SE0104330D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
SE0104332D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
FR2833842B1 (fr) 2001-12-21 2004-02-13 Aventis Pharma Sa Compositions pharmaceutiques a base de derives d'azetidine
AU2003209388A1 (en) 2002-01-29 2003-09-02 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
AU2003219934A1 (en) 2002-03-06 2003-09-22 Merck And Co., Inc. Method of treatment or prevention of obesity
ATE486842T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
AR038966A1 (es) 2002-03-18 2005-02-02 Solvay Pharm Bv Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
AU2003215024B2 (en) 2002-03-26 2008-02-21 Merck Sharp & Dohme Corp. Spirocyclic amides as cannabinoid receptor modulators
ES2192494B1 (es) 2002-03-27 2005-02-16 Consejo Superior De Investigaciones Cientificas Derivados de 1,2,4-triazol con propiedades cannabinoides.
EP1492784A4 (en) 2002-03-28 2006-03-29 Merck & Co Inc SUBSTITUTED 2,3-DIPHENYLPYRIDINES
AU2003226149A1 (en) 2002-04-05 2003-10-27 Merck & Co., Inc. Substituted aryl amides
FR2838438A1 (fr) 2002-04-11 2003-10-17 Sanofi Synthelabo Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant
FR2838439B1 (fr) 2002-04-11 2005-05-20 Sanofi Synthelabo Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant
EP1499306A4 (en) 2002-04-12 2007-03-28 Merck & Co Inc BICYCLIC AMIDE
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
AU2003250117B2 (en) 2002-07-29 2007-05-10 F. Hoffmann-La Roche Ag Novel benzodioxoles
ATE375349T1 (de) 2002-08-02 2007-10-15 Merck & Co Inc Substituierte furo(2,3-b)pyridin derivate
AU2003296895A1 (en) 2002-08-20 2004-05-04 The Regents Of The University Of California Combination therapy for controlling appetites
HRP20050053A2 (en) 2002-09-19 2005-04-30 Solvay Pharmaceuticals B.V. 1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands
AU2003275242B2 (en) 2002-09-27 2010-03-04 Merck Sharp & Dohme Corp. Substituted pyrimidines
BR0314872A (pt) 2002-10-18 2005-08-02 Pfizer Prod Inc Ligandos do receptor canabinóide e usos dos mesmos
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
WO2004058145A2 (en) 2002-12-19 2004-07-15 Merck & Co., Inc. Substituted amides
GB0230087D0 (en) 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
ES2309383T3 (es) 2003-01-02 2008-12-16 Hoffmann La Roche Pirrolil tiazoles y su empleo como agonistas inversos de receptores cb1.
TW200413328A (en) 2003-01-02 2004-08-01 Hoffmann La Roche Novel CB 1 receptor inverse agonists
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
ATE472548T1 (de) 2003-02-13 2010-07-15 Sanofi Aventis Deutschland Substituierte hexahydro-pyrazino(1,2-a)pyrimidin- 4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
AU2004212043A1 (en) 2003-02-13 2004-08-26 Sanofi-Aventis Deutschland Gmbh Nitrogen-substituted hexahydropyrazino(1,2-a)pyrimidine-4,7-dione derivatives, method for the production and use thereof as medicaments
US7169797B2 (en) * 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
US20040167188A1 (en) * 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
WO2004078261A1 (en) 2003-03-07 2004-09-16 The University Court Of The University Of Aberdeen Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
AR045496A1 (es) * 2003-08-29 2005-11-02 Schering Corp Analolgos de benzimidazolpiperidinas 2- substiyuidas como antagonistas de los receptores de la hormona que concentra melanina selectivos para el tratamiento de la obesidad y trastornos relacionados
US8207147B2 (en) 2003-12-24 2012-06-26 Prosidion Limited Heterocyclic derivatives as GPCR receptor agonists
BRPI0517232A (pt) 2004-11-02 2008-10-07 Banyu Pharma Co Ltd composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, ativador da glicocinase, e, agentes terapêuticos e/ou profiláticos para diabetes e para obesidade
KR20070091038A (ko) 2004-12-24 2007-09-06 프로시디온 리미티드 Ｇ-단백질 결합 수용체(ｇｐｒ116) 효능제 및 비만 및당뇨병을 치료하기 위한 이의 용도
EP1838706A1 (en) 2004-12-24 2007-10-03 Prosidion Limited G-protein coupled receptor agonists
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
US20090325924A1 (en) 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
AU2006264649A1 (en) * 2005-06-30 2007-01-11 Prosidion Limited GPCR agonists
JP2008545010A (ja) 2005-06-30 2008-12-11 プロシディオン・リミテッド Ｇタンパク質共役受容体アゴニスト
JP2008545008A (ja) 2005-06-30 2008-12-11 プロシディオン・リミテッド Ｇｐｃｒアゴニスト
NZ571869A (en) * 2006-04-06 2011-11-25 Prosidion Ltd Heterocyclic GPCR agonists

Also Published As

Publication number Publication date
CY1112483T1 (el) 2015-12-09
HRP20110852T1 (hr) 2011-12-31
WO2008081204A1 (en) 2008-07-10
EA200900877A1 (ru) 2010-02-26
CA2674348A1 (en) 2008-07-10
EP2114933A1 (en) 2009-11-11
HK1135703A1 (en) 2010-06-11
RS52065B (sr) 2012-06-30
SI2114933T1 (sl) 2012-01-31
EA015129B1 (ru) 2011-06-30
JP2010514828A (ja) 2010-05-06
DK2114933T3 (da) 2012-01-02
US20100048632A1 (en) 2010-02-25
EP2114933B1 (en) 2011-09-07
ES2373181T3 (es) 2012-02-01
BRPI0806498A2 (pt) 2014-04-22
PL2114933T3 (pl) 2012-02-29
EP2377863A1 (en) 2011-10-19
PT2114933E (pt) 2011-12-20

Similar Documents

Publication Publication Date Title
DK2114933T3 (da) Piperidin-GPCR-agonister
MX2009007180A (es) Agonistas del receptor acoplado a la proteina g de la piperidina.
ATE557024T1 (de) Piperidinverbindungen als gpcr-agonisten
ATE557023T1 (de) Piperidinylverbindungen als gpcr-agonisten
NO20084307L (no) Heterocykliske GPCR agonister
WO2007003962A3 (en) Gpcr agonists
WO2007003961A3 (en) Gpcr agonists
MA32467B1 (fr) Derives de piperidinyle agonistes de gpcr
CY1112474T1 (el) Πιπεριδινικοι gpcr αγωνιστες
LTC2137143I2 (lt) Pleuromutilino dariniai, skirti mikrobų sukeltų ligų gydymui
WO2007116230A8 (en) Azetidine derivatives as g-protein coupled receptor (gpr119 ) agonists
NO20080052L (no) G-Protein kopplede reseptoragonister
EA200900878A1 (ru) Пиперидиновые агонисты gpcr
DOP2012000006A (es) Agonista de gpr119
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
NO20075082L (no) Pyridin-3-karboksamidderivater som CB1-inversagonister
EA200900879A1 (ru) Пиперидиновые агонисты gpcr
NO20090173L (no) Kondensert spiroketalderivat og anvendelse derav som legemiddel for a behandle diabetes
NO20093200L (no) Tiazolidinderivater
ATE442349T1 (de) Diacylglycerol-acyltransferase-hemmer
EA201100612A1 (ru) Новые производные 2-амидотиадиазола
EA201000439A1 (ru) Бензотиазолы в качестве модуляторов рецептора грелина
WO2010052144A3 (en) Neuropeptide-2-receptor (y-2r) agonists and uses thereof
ECSP066883A (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes
EA201200868A1 (ru) Ингибиторы диацилглицеролацилтрансферазы

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2114933

Country of ref document: EP